SEARCH

SEARCH BY CITATION

References

  • 1
    Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette–Guerin in the treatment of superficial bladder tumours. J Urol 1976; 116:180 3.
  • 2
    Lamm DJ, Van Der Meijden APM, Akaza H et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses. Int J Urol 1995; Suppl. 2:22 25.
  • 3
    Pawinsky A, Sylvester R, Kurth K-H et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of Stage Ta Tl bladder cancer. J Urol 1996; 156:1934 40.
  • 4
    Zbar B, Bernstein ID, Bartlett GL, Hanna MG Jr, Rapp HJ. Immunotherapy of cancer: regression of intradermal tumours and prevention of growth of lymph node metastases after intralessional injection of living Mycobacterium bovis. J Natl Cancer Inst 1972; 49:119 30.
  • 5
    Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: fifteen year outcome. Br J Urol 1997; 80:762 8.
  • 6
    Guerin C. The history of BCG. In: RosenthalSR, ed. BCG vaccine: tuberculosis-cancer. Littleton, MA: PSG Publishing Co. Inc., 37.
  • 7
    Mackaness GB, Auclair DJ, Iagrange PH. Immunopotentiation with BCG immune response to different strains and preparations. J Natl Cancer Inst 1973; 5:1655.
  • 8
    Witjes JA, Van Der Meijden APM, Witjes WP. A randomized prospective study comparing intravesical instillations of Mitomycin-C, BCG-Tice and BCG-Rivm in pTa-pTl tumours and primary carcinomas in situ of the urinary bladder. Eur J Urol 1993; 12:1672.
  • 9
    De Boer EC, De Jong WH, Steerenberg PA et al. Induction of urinary IL-1, IL-2, IL-6 and IFN during intravesical immunotherapy with BCG in superficial bladder cancer. Cancer Immunol Immunother 1992; 34:306 12.
  • 10
    Reijke TM, De Boer LC, De Kurt K-H, Schamhart DHJ. Urinary cytokines during intravesical Bacillus Calmette–Guerin therapy for superficial bladder cancer. Processing stability and prognostic value. J Urol 1996; 155:477 82.
  • 11
    Luo Y, Chen X, Han R, O'Donnell MA. Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001; 123 :264 270.